使用优特克单抗治疗期间的多灶性皮肤利什曼病 - Suppr

Suppr

超能文献

Plurifocal cutaneous leishmaniasis during treatment with ustekinumab.

作者信息

Rakotonarivo Louva, Lons-Danic Dominique, Janier Michel

机构信息

Dermatology Department, Fondation Hôpital Saint-Joseph, Paris, France.

出版信息

JAAD Case Rep. 2018 Mar 31;4(4):298-300. doi: 10.1016/j.jdcr.2017.09.020. eCollection 2018 May.

DOI:10.1016/j.jdcr.2017.09.020

PMID:29693053

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5911776/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3a0/5911776/416bf4bd7682/gr1.jpg

相似文献

Plurifocal cutaneous leishmaniasis during treatment with ustekinumab.使用优特克单抗治疗期间的多灶性皮肤利什曼病

JAAD Case Rep. 2018 Mar 31;4(4):298-300. doi: 10.1016/j.jdcr.2017.09.020. eCollection 2018 May.

Analysis of the clinical response and changes in the expression of TNF-α and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumab.分析乌司奴单抗治疗寻常型银屑病患者的临床应答和 TNF-α 及其 TNFR1 和 TNFR2 受体表达的变化。

Adv Clin Exp Med. 2020 Feb;29(2):235-241. doi: 10.17219/acem/112607.

Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.优特克单抗在未使用过抗肿瘤坏死因子-α药物和对抗肿瘤坏死因子-α药物耐药的日本银屑病患者中的疗效比较。

Int J Dermatol. 2015 Oct;54(10):1194-8. doi: 10.1111/ijd.12859. Epub 2015 May 27.

Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.日本银屑病及银屑病关节炎患者的血清C反应蛋白水平：生物制剂的长期差异效应

J Dermatol. 2016 Jul;43(7):779-84. doi: 10.1111/1346-8138.13213. Epub 2015 Dec 24.

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.乌司奴单抗与依那西普治疗中重度银屑病的比较。

N Engl J Med. 2010 Jan 14;362(2):118-28. doi: 10.1056/NEJMoa0810652.

The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment.分析乌司奴单抗治疗寻常型银屑病的治疗潜力。

Dermatol Ther. 2019 May;32(3):e12843. doi: 10.1111/dth.12843. Epub 2019 Feb 18.

PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.PACE研究：中重度银屑病患者使用生物制剂实现银屑病面积和严重程度指数（PASI）100应答的真实情况

J Dermatolog Treat. 2018 Aug;29(5):481-486. doi: 10.1080/09546634.2017.1395805. Epub 2017 Nov 10.

Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.里莎珠单抗与乌司奴单抗治疗斑块状银屑病：批判性评价。

Br J Dermatol. 2019 Jun;180(6):1348-1351. doi: 10.1111/bjd.17624. Epub 2019 Mar 27.

Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.CD84、IL12B 和 TNFAIP3 基因多态性与银屑病患者对生物制剂的反应相关。

Br J Dermatol. 2017 May;176(5):1288-1296. doi: 10.1111/bjd.15005. Epub 2017 Apr 10.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.在中重度斑块型银屑病中的疗效和安全性（UltIMMa-1 和 UltIMMa-2）：两项双盲、随机、安慰剂对照和乌司奴单抗对照的 3 期临床试验结果。

Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.

引用本文的文献

Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU.炎症性肠病患者的利什曼病：GETECCU的一项全国多中心研究。

United European Gastroenterol J. 2025 Jun;13(5):674-684. doi: 10.1002/ueg2.12740. Epub 2025 Jan 8.

A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases.对接受药物诱导免疫抑制以治疗皮肤病、风湿病和胃肠病的患者中利什曼病的全面系统评价。

Rev Inst Med Trop Sao Paulo. 2020;62:e28. doi: 10.1590/s1678-9946202062028. Epub 2020 May 11.

Severe acute toxoplasmosis infection following ustekinumab treatment in a patient with psoriasis vulgaris.一名寻常型银屑病患者接受乌司奴单抗治疗后发生严重急性弓形虫感染。

BMJ Case Rep. 2019 Aug 15;12(8):e230415. doi: 10.1136/bcr-2019-230415.

本文引用的文献

Cutaneous and visceral leishmaniasis during anti-TNFα therapy.抗TNFα治疗期间的皮肤利什曼病和内脏利什曼病

Wien Med Wochenschr. 2017 Mar;167(3-4):78-82. doi: 10.1007/s10354-016-0527-1. Epub 2016 Nov 10.

Visceral leishmaniasis in a psoriatic arthritis patient treated with methotrexate.一名接受甲氨蝶呤治疗的银屑病关节炎患者发生内脏利什曼病。

Infez Med. 2014 Sep;22(3):230-5.

The current status of cutaneous leishmaniasis in Morocco.摩洛哥皮肤利什曼病的现状。

Turkiye Parazitol Derg. 2014;38(1):5-8. doi: 10.5152/tpd.2014.1401.

Cutaneous leishmaniasis in North Africa: a review.北非的皮肤利什曼病：综述

Parasite. 2014;21:14. doi: 10.1051/parasite/2014014. Epub 2014 Mar 14.

Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases).抗肿瘤坏死因子治疗期间的利什曼病：4 例报告及文献复习（另加 28 例）。

Semin Arthritis Rheum. 2013 Oct;43(2):152-7. doi: 10.1016/j.semarthrit.2013.01.006. Epub 2013 Jun 15.

[Therapy of leishmaniasis in France: consensus on proposed guidelines].[法国利什曼病的治疗：拟议指南的共识]

Presse Med. 2011 Feb;40(2):173-84. doi: 10.1016/j.lpm.2010.09.023. Epub 2010 Nov 23.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).优特克单抗（一种人白细胞介素-12/23单克隆抗体）治疗银屑病患者的疗效和安全性：一项随机、双盲、安慰剂对照试验（PHOENIX 2）的52周结果

Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).优特克单抗（一种人白细胞介素-12/23单克隆抗体）治疗银屑病患者的疗效和安全性：一项随机、双盲、安慰剂对照试验（PHOENIX 1）的76周结果

Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4.

The role of IL-12 in maintaining resistance to Leishmania major.白细胞介素-12在维持对硕大利什曼原虫抗性中的作用。

J Immunol. 2002 Jun 1;168(11):5771-7. doi: 10.4049/jimmunol.168.11.5771.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验